Overview

Tranexamic Acid During Upper GI Endoscopic Resection Procedures

Status:
Not yet recruiting

Trial end date:
2026-02-01

Target enrollment:
0

Participant gender:
All

Summary

Endoscopic resection of gastrointestinal lesions may prevent cancer. However, resection is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of upper gastrointestinal lesions.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Assaf-Harofeh Medical Center

Treatments:

Epinephrine
Tranexamic Acid

Criteria

Inclusion Criteria:

- Patients referred for endoscopic resection of a non-neoplastic and neoplastic lesions
in the upper GI presenting to our tertiary academic center.

- Age > 18 years

Exclusion Criteria:

- patients with histories of allergic reactions to TXA

- history of seizures

- pregnancy